ReviewFrontiers in bioscience (Landmark edition)2009
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.
Review in Frontiers in bioscience (Landmark edition), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- HBCVTr: an end-to-end transformer with a deep neural network hybrid model for anti-HBV and HCV activity predictor from SMILES.Scientific reports · 2024Article
- Alterations in N-glycosylation of HCV E2 Protein in Children Patients with IFN-RBV Therapy Failure.Pathogens (Basel, Switzerland) · 2024Article
- Review
- Hepatitis C Viral Infection in Children: Updated Review.Pediatric gastroenterology, hepatology & nutrition · 2016Review
- Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver Diseases.Oxidative medicine and cellular longevity · 2016Review
- Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E.PloS one · 2014Article
- Immunoregulation through membrane proteins modified by reducing conditions induced by immune reactions.European journal of immunology · 2013Review
- Hepatitis C variability, patterns of resistance, and impact on therapy.Advances in virology · 2012Article
- Review
- Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.World journal of gastroenterology · 2011Article
- Resolving the infection process reveals striking differences in the contribution of environment, genetics and phylogeny to host-parasite interactions.BMC biology · 2011Article
- Cell entry of enveloped viruses.Advances in genetics · 2011Review
- Hepatitis C virus experimental model systems and antiviral drug research.Virologica Sinica · 2010Review
- Strategies for antiviral screening targeting early steps of virus infection.Virologica Sinica · 2010Review
- Targeting HCV entry for development of therapeutics.Viruses · 2010Article
- Article
- Hepatic tight junctions: from viral entry to cancer metastasis.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a major impact on public health. The liver is the primary target organ of HCV, and the hepatocyte is its primary target cell. Attachment of the virus to the cell surface followed by viral entry is the first step in a cascade of interactions between the virus and the target cell that is required for successful entry into the cell and initiation of infection. Using recombinant HCV envelope glycoproteins and HCV pseudotype particles, several cell surface molecules have been identified interacting with HCV during viral binding and entry. These include CD81, highly sulfated heparan sulfate, the low-density lipoprotein receptor, scavenger receptor class B type I and claudin-1. Treatment options for chronic HCV infection are limited and a vaccine to prevent HCV infection is not available. Interfering with HCV entry holds promise for drug design and discovery as the understanding of molecular mechanisms underlying HCV interaction with the host cell is advancing. The complexity of the virus entry process offers several therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.